article thumbnail

STAT+: Senator launches investigation into GSK’s asthma inhaler maneuvers

STAT

In a letter sent to the company, the lawmaker maintained that the decision to discontinue its inhaler in January 2024 has since had “life-threatening consequences for patients” and contributed to a spike in hospitalizations.

article thumbnail

Incubators and innovation hubs: Accelerating entrepreneurship in life sciences

Express Pharma

In India, the life sciences innovation, which includes pharma, biotech, and medtech, is valued at $30 billion in 2024. “The first wealth is health,” said the American philosopher Ralph Waldo Emerson in 1860, and strides in life sciences entrepreneurship pronouncedly affect this form of wealth in any country.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FOPE & PharmaState Academy host Session 12 of the PULSE series

Express Pharma

On December 29, 2024, the Federation of Pharma Entrepreneurs (FOPE) and PharmaState Academy hosted Session 12 of the PULSE (Pharma Upgradation & Learning Series for Excellence) initiative, focusing on Complaints and Product Recall. The session provided clarity on the guidelines and cleared the queries of the pharma professionals.

article thumbnail

The European Market Access Lag: 2021–2024

Pharmaceutical Technology

On average, 58% of branded drugs approved between 2021 and 2024 in Europe have either fully or restricted reimbursement. First, the access landscape for 220 originator medicines approved by the EMA between 2021–2024 was assessed. Reimbursement status for each brand per European market was analysed during this period.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. 📆 November 21, 2024 at 11:00 AM PST, 2:00 PM EST, 7:00 PM GMT

article thumbnail

Restoring regulatory excellence “central” to UK life science competitiveness

European Pharmaceutical Review

Summary of ABPI’s recommendations • Enhancing communications, transparency, and accountability • Improving resourcing and expertise to support its regulatory functions • Strengthening the regulatory framework with flexible licensing routes, expedited clinical trial approvals and horizon scanning capabilities.

article thumbnail

CNS innovator oligonucleotide licensing value up 339% from £2bn in 2024

Pharmaceutical Technology

Innovator oligonucleotide-based drugs targeting central nervous system (CNS) indications witnessed a 339% ($2.17bn) increase in total licensing agreement deal value from 2023 to 2024, reaching a total deal value of $2.81bn, according to GlobalData’s Pharma Intelligence Center Deals Database.